Vertex Buys ViaCyte in Synergistic Deal Aimed at Curing Type 1 Diabetes | BioSpace
Vertex to acquire ViaCyte, targeting type 1 diabetes
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
International Medical Students' Research Association - The new remarkable treatment for Type 1 diabetes! Type 1 diabetes (T1D) is a chronic condition in which the pancreas produces little or no insulin. Insulin
Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more - The Niche
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Vertex eyes type 1 diabetes cure with biotech acquisition - PMLiVE
Type 1 Diabetes Cures in Spotlight with Vertex Deal
Vertex Branches Into Diabetes, Acquiring Semma for $950 Million | BioSpace
Stem cell trial biggest 'step toward a cure' for Type 1 Diabetes in 100 years, researchers say
Harvard diabetes researcher details science behind potential breakthrough – Harvard Gazette
Stem Cell-Based 'Cure' for Type 1 Diabetes
New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials
First person cured of type 1 diabetes thanks to stem cells
ViaCyte's Future 'Functional Diabetes Cure' for Diabetes
Vertex signs licence deal with CRISPR for diabetes therapies
In a new stem cell study, a cure for Type 1 diabetes appears tantalizingly close | Salon.com
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes | Business Wire
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech | Evaluate
Vertex has initial success in new diabetes project — MedWatch
Could Vertex Have a Cure for Type 1 Diabetes on the Way? | The Motley Fool
Creating the next cell therapies for diabetes – Eric Bender
